The phase III KEYFORM-007 study (ClinicalTrials.gov identifier:
NCT05064059
) evaluated the efficacy and safety of coformulated favezelimab/pembrolizumab versus standard-of-care (SOC) in PD-L1–positive microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC). We present re...
N. Segal, Maria Passhak, F. Kose et al.· JCO Oncology Advances· 0 citations
The gut microbiome is a modifiable determinant of response to immune checkpoint inhibitors (ICI), positioning antibiotic exposure as a critical yet under-recognized risk factor for worse survival outcomes in immuno-oncology. As nearly 30% of ICI-treated patients receive antibiotics and indications of cancer immunothera...
Serena Porcari, L. Bolte, J. Björk et al.· Cancer Cell· 0 citations
BACKGROUND
Accurate preoperative staging is essential for risk stratification and treatment planning in localized colon cancer (lCC), particularly in the context of emerging neoadjuvant strategies. However, the reproducibility of CT-based classification and its concordance with pathology remain incompletely defined....
Giovanni Trovato, M. Calegari, P. Testa et al.· Clinical colorectal cancer· 0 citations
Liquid biopsy guided anti-EGFR rechallenge therapy is gaining ground as a potential option for patient with refractory metastatic colorectal cancer. However, the identification of potential biomarkers to implement patient's stratification is required. The CAVE-2 GOIM trial investigated the role of rechallenge with cetu...
Davide Ciardiello, G. Martini, L. Boscolo Bielo et al.· The journal of liquid biopsy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.